NFE2L2 and COVID-19: A recent study demonstrated that expression of Nrf2-driven genes are suppressed in biopsies of COVID-19 patients by the treatment of cells with Nrf2 agonists, and these agonists were shown to be effective in limiting viral replication and suppressing host inflammatory responses of several human pathogenic viruses, including SARS-CoV-2 (Olagnier et al., 2020).